Pipeline
De-risking the STC platform one study at a time.
Each study is designed to answer the next critical scientific, formulation, or translational question. Development plans are forward-looking and may change as additional data are generated.
Molecular design
Design of the STC prodrug platform, informed by the known metabolic liabilities of testosterone and a physiology-led approach to liver activation.
In vitro activation studies
Liver-cell studies across four species (mouse, rat, dog, and human) evaluating conversion efficiency relative to a reference compound.
Rodent proof-of-concept
Mouse studies evaluating testosterone levels following administration, alongside molecular simulations of binding to the liver enzymes involved in activation.
Analog synthesis and in vitro screening
Ongoing synthesis and screening of STC analogs to guide lead selection, alongside structured customer and stakeholder discovery.
Translational PK and formulation
Planned rat and dog pharmacokinetic studies and formulation feasibility work to inform lead analog and formulation strategy.
IND-enabling toxicology and CMC
Future toxicology studies and chemistry, manufacturing, and controls (CMC) work to support eventual FDA engagement.
Development plans are forward-looking and may change as additional data are generated.